Date Title Description PDF
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
22 Feb 2022 On buy-back programmes ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022.     Download
16 Feb 2022 On business and financial situation Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years       Download
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download

Pages

Date Title Description PDF
11 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 7 June 2024 and 11 June 2024 and end of the share buyback program Download
07 Jun 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 31 May and 6 June 2024 Download
31 May 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 24 May and 30 May 2024 Download
24 May 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 May and 23 May 2024 Download
21 May 2024 Announcement of general shareholders’ meeting Publication of the announcement of the call to the General Shareholders’ Meeting and the documentation related thereto.   Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages